Guggenheim analyst Vamil Divan initiated coverage of Vera Therapeutics with a Buy rating and $27 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VERA:
- Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results
- Vera Therapeutics announces upcoming milestones
- Vera Therapeutics expects cash to fund operations into 2026
- Vera Therapeutics reports Q2 EPS (46c), consensus (69c)
- Vera Therapeutics announces efficacy, safety results Phase 2b ORIGIN trial